XINING, China, July 27, 2024 /PRNewswire/ — vivo today held the 2024 vivo Imaging Conference in Xining, China, where it showcased vivo’s latest advancements in imaging technologies. The company presented its progressive strategies surrounding three new trends in mobile imaging: imaging security, 3D imaging/XR and health imaging. In addition, the results of the VISION+ Mobile PhotoAwards 2024 were also revealed, with photographer He Jinyi’s captivating work, “A Fleeting Moment in Endless Time,” earning the Best Photograph of the Year.

The event saw the presence of several distinguished guests and industry partners, including Yu Meng, Vice President, Vice President of Imaging at vivo; Li Zhuo, Senior Director of Imaging Product at vivo; Sebastian Döntgen, Head of Marketing, Category Management and Sales, ZEISS Consumer Products; world-renowned color photographer Alex Webb; visual artist Duan Yueheng; director Xin Shuang; visual artist Li Xiaoliang; and Song Wen, founder of the FIRST International Film Festival.

“Over the past decade, we have steadfastly adhered to a strategy of independent and collaborative R&D, continuously advancing ‘human-centric professional imaging.’ We strive to be on par with the benchmarks set by professional imaging equipment, photography teams, and post-production capabilities. Going forward, vivo is committed to addressing user needs, pushing the boundaries of imaging technology in collaboration with global partners, and forging a new vision for the future of imaging. Our ultimate goal is to contribute positively to society and enrich people’s lives,” said Yu Meng.

vivo Announced Winners of VISION+ Mobile PhotoAwards 2024

In recent years, vivo has built a rich imaging culture ecosystem through initiatives like the VISION+ Mobile Photo Awards, co-organized with ZEISS, sparking public creativity and enthusiasm.

vivo announced the winners of the VISION+ Mobile Photo Awards 2024 at the event. Over a span of seven months, the competition received over 600,000 entries worldwide, all captured using vivo smartphones. After rigorous evaluation, a total of 25 award-winning works stood out, including four entries from photographers overseas. Among these are “Happy Together” by Indonesian photographer Maya Nurikawati, “O Shape” by Burmese photographer Aung Chan Thar, “Look Like Painting” by Burmese photographer Win Ei Phu, and “Friendship Goals” by Indian photographer Pradiptamoy Paul.

Among the winning entries across six categories, “A Fleeting Moment in Endless Time” by photographer He Jinyi was honored as the Best Photo of the Year. This photo captures a magnificent moment of a meteor streaking across the sky over a dracaena cinnabari on Socotra Island, a tree species known for its longevity of tens of thousands of years. Using the Handheld Astro feature and long exposure capability of vivo X100 Pro, the photographer precisely captured the dazzling beauty of the night sky.

vivo Unveils Three New Trends in Mobile Imaging

As a pioneer in mobile imaging, vivo has unveiled three key future trends: imaging security, 3D imaging/XR, and health imaging, and shared the company’s insights and explorations into the technology industry ecosystem and the future of imaging.

To protect user image data and privacy, as well as to prevent the misuse of image information, vivo is committed to further strengthening its image security technology, establishing a more reliable imaging experience and digital lifestyle for users. In terms of authenticity, vivo consistently innovates in the marking technology for photos and videos. By collaborating with security application and service providers, vivo aims to build a transparent and trustworthy ecosystem for content creation and sharing, achieving the widespread applicability of image security identification. This is also a major direction that vivo and ZEISS will jointly explore.

In terms of 3D imaging and XR technologies, vivo introduces cutting-edge 3D imaging capabilities to vivo X100 Ultra^[1] for the first time, delivering an immersive visual experience. The synchronization of multiple cameras and 3D image processing technology enables the capture of vibrant and lifelike 3D images, which are then stored in a proprietary stereo format. vivo, in partnership with Rokid, pioneers an integrated experience in the industry, blending content creation and consumption. This synergistic relationship empowers the smartphone to capture stunning 3D imagery, while AR glasses elevate the consumption experience, unlocking its full potential. In the field of XR technology, vivo is dedicated to improving the immersive and panoramic viewing experience by projecting distant scenes onto AR glasses or virtual screens. Looking ahead, Yu Meng revealed at the event that vivo will launch MR (Mixed Reality) wearable devices in 2025, further driving the development of spatial imaging.

In the field of smart health, vivo is actively exploring innovative applications of mobile imaging in healthcare services, aiming to develop solutions that are more intelligent and convenient.

Marking a decade of imaging milestones, vivo, from this new starting point, will continue to uphold its user-oriented approach. With a genuine passion for innovation and in collaboration with like-minded partners, vivo will persist in exploring the boundaries of imaging, jointly shaping a visionary blueprint for the future of mobile imaging.

About vivo

vivo is a technology company that creates great products based on a design-driven value, with smart devices and intelligent services as its core. The company aims to build a bridge between humans and the digital world. Through unique creativity, vivo provides users with an increasingly convenient mobile and digital life.

While bringing together and developing the best local talents to deliver excellence, vivo is supported by a network of R&D centers including Shenzhen, Dongguan, Nanjing, Beijing, Hangzhou, Shanghai and Xi’an, focusing on the development of state-of-the-art consumer technologies, including 5G, artificial intelligence, industrial design, photography and other up-and-coming technologies. vivo has also set up an intelligent manufacturing network (including those authorized by vivo), with an annual production capacity of nearly 200 million smartphones. As of now, vivo has branched out its sales network across more than 60 countries and regions, and is winning more than 500 million users worldwide with its superior products and services.

Following the company’s core values, which include Benfen*, user-orientation, design-driven value, continuous learning and team spirit. vivo has implemented a sustainable development strategy, with the vision of developing into a healthier, more sustainable world-class corporation.

*”Benfen” is a term describing the attitude on doing the right things and doing things right – which is the ideal description of vivo’s mission to create value for society.

Source

• The positive CHMP opinion is based on results from the Phase II PHAROS trial,^[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma indication^[1]
• The European Commission decision for BRAFTOVI^® (encorafenib) + MEKTOVI^® (binimetinib) is expected later this year.

CASTRES, France, July 26, 2024 /PRNewswire/ — Pierre Fabre Laboratories announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of BRAFTOVI^® (encorafenib) in combination with MEKTOVI^® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF^V600E mutation. The positive opinion will now be submitted to the European Commission (EC) with a decision on EU marketing authorisation (MA) expected later this year.

Eric Ducournau, Chief Executive Officer, Pierre Fabre Laboratories said: “The positive CHMP opinion marks a pivotal step in our commitment to delivering an additional effective targeted treatment option for patients with advanced NSCLC with a BRAF^V600E mutation, who at present have limited treatment options. We look forward to the European Commission’s decision to make BRAFTOVI^® + MEKTOVI^® available to non-small cell lung cancer patients in Europe.”

The CHMP positive opinion is supported by data from the global, open-label, multicentre, non-randomised Phase II PHAROS trial, which included 98 patients from 56 study centres across 5 countries.^[1]

At primary analysis (cut-off date: September 22, 2022), the primary endpoint of the trial (objective response rate [ORR] determined by independent radiology review [IRR]) was met. The PHAROS trial showed that in patients with advanced NSCLC with a BRAF^V600E mutation, BRAFTOVI^® and MEKTOVI^® provided a meaningful clinical benefit with an ORR of 75% (95% CI: 62, 85) in treatment naïve patients (n=59), with 59% of them maintaining their response for at least 12 months. For those patients who had received prior therapy (n=39), the ORR was 46% (95% CI: 30, 63), with 33% maintaining their response for at least 12 months.^[1]

CONTACT: Laurence MARCHAL laurence.marchal@pierre-fabre.com

Source

ABU DHABI, UAE, July 26, 2024 /PRNewswire/ — Warner Bros. World™ Yas Island, Abu Dhabi, the region’s largest indoor theme park, is thrilled to announce a groundbreaking extension to its partnership with Etihad Airways, marking a monumental milestone in its history. This exciting collaboration was unveiled to the public on July 25 at a spectacular launch event and will bring the excitement of Warner Bros. World™ to the skies with the launch of the world’s first Warner Bros. World™ branded aircraft, taking guests’ pre-theme park experience to new heights.

To view the Multimedia News Release, please click: 
https://www.multivu.com/players/uk/9281951-warner-bros-world-yas-island-abu-dhabi-etihad-airways-partnership/

The partnership between Warner Bros. World™ and Etihad Airways represents the largest collaboration for the theme park to date. As part of this captivating initiative, an Etihad Airways aircraft – Boeing 787-10 Dreamliner – has been creatively decorated with iconic Warner Bros. characters. On one side, guests will be greeted by the mischievous antics of iconic Classic Animation characters like the Looney Tunes and Tom and Jerry, while the other side showcases the heroic feats of beloved DC Super Heroes.

All young guests aged up to 10 years old, flying on Etihad Airways longer flights will receive brand new Warner Bros. World™ Kids Packs that are being rolled out across the network this summer. Bursting with creativity, these packs are designed to entertain young travelers with activities that inspire them to draw their favorite superheroes and engage in a variety of fun tasks throughout the flight, ensuring every moment is packed with adventure. Infants will receive a DC Super Hero themed soft blanket, while juniors will receive goodies such as a branded backpack, Super Hero cape, water bottle and activity kit.

Warner Bros. World™ will also debut its exclusively branded, dedicated children’s lounge within the Etihad Airways Lounge at Zayed International Airport in Abu Dhabi. This whimsical lounge will transport travelers into the incredible universe of Warner Bros. World™, offering a one-of-a-kind experience that brings the wit of the park to the airport, making every journey as delightful as a visit to the theme park itself.

Expressing his enthusiasm about the partnership, Mohamed Abdalla Al Zaabi, Group CEO of Miral, said: “We are absolutely delighted to partner with Etihad Airways to bring the first-ever Warner Bros. World™ branded aircraft to fans. This collaboration not only expands the customer experience, but also extends the thrill of Warner Bros. World™ beyond our park’s walls, creating a super vacation with long lasting unforgettable memories for passengers of all ages.”

Adding to this, Antonoaldo Neves, Chief Executive Officer, Etihad Airways, said: “Building on the strong reputation we have built as a family-friendly airline, we’re thrilled to take our partnership with Warner Bros. World™ to the next level. Our Looney Tunes and DC Super Hero themed aircraft will take our brands to destinations worldwide promoting one of Abu Dhabi’s many attractions. We look forward to welcoming more and more visitors inspired to visit our home, Abu Dhabi, and in particular delighting our Little VIP guests while they journey with us.”

 

Warner Bros. World™ brings the park experience directly to travelers with its first-ever branded aircraft in partnership with Etihad Airways

Taghrid Al Saeed (Executive Director of Group Comms & Destination Marketing – Miral Destinations), Liam Findlay (CEO of Miral Destinations), Daniel Hoffman (CEO of Engineering – Etihad Airways), Mohamed Abdalla Al Zaabi (Group CEO – Miral), Antonoaldo Neves (Chief Executive Officer – Etihad Airways), Turky Al Hammadi (Director of Product and Hospitality – Etihad Airways) and Akhil Anumolu (Senior Vice President E-commerce, Digital, Marketing and Loyalty – Etihad Airways)

Source: Warner Bros. World™ Yas Island

Source

JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ — Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts in Jakarta! MHTC is the pioneer in organising healthcare expo in Indonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two events in Indonesia in the first half of 2024, and the third event in July 2024 held in Jakarta concluded with resounding success with a remarkable attendance of 3,000 visitors resulting in generation of high level of leads and forging of strategic partnerships.

The MHTX Jakarta 2024 was held from 18 to 21 July 2024 at The Forum Atrium, Mall Kelapa Gading 3. It was participated by a record 20 top notch MHTC member hospitals, and for this event both Sabah Tourism Board and Sarawak Tourism board took the pavilion to showcase their state’s tourism products.

“We are thrilled by the overwhelming response to MHX Jakarta 2024,” said Dato’ Syed Md Hasrin Tengku Hussin, Ambassador of Malaysia to Indonesia, who graced the event’s opening ceremony. “This expo not only underscores Malaysia’s position as a good option of destination for healthcare but also strengthens the bonds between our nations through healthcare excellence.”

The event saw extensive of 26 media coverage in Indonesia, highlighting Malaysia’s accredited medical treatments in cardiology, oncology, orthopaedics, hepatology, IVF, gastroenterology, ophthalmology, and internal medicine. attraction, reflecting Indonesian patients’ growing trust in Malaysia’s healthcare expertise.

The first quarter of 2024 saw a 24% increase in Indonesian health tourism volume. It reflects the trust and confidence that Indonesian patients have in Malaysia as a trusted and reliable destination for their medical needs. For that, MHTC aims to continue enhancing its offerings, focusing on both curative and preventive care.

MHX Jakarta July 2024 featured promotions and interactive activities supported by partners Bank Muamalat Indonesia and JavaMifi, offering attendees exciting opportunities to win prizes while learning about Malaysia’s healthcare advantages. From quality healthcare facilities accredited globally to affordable treatment costs and seamless patient experiences, Malaysia would continue to be the preferred option for Indonesian health tourists.

“The success of MHX Jakarta July 2024 would not have been possible without the dedication of our member hospitals and partners,” remarked the MHTC VP MarComms Mr. Lokman Izam. “Their commitment to excellence and innovation has set new benchmarks in healthcare accessibility for our Indonesian visitors.”

As MHX Jakarta July 2024 concluded on a high note, we are moving to Surabaya, where MHTC plans its next healthcare expo. Stay tuned for further details as we continue to bring Malaysia’s award-winning healthcare closer to healthcare patients in Indonesia and beyond.

#ExperienceMalaysiaHealthcare #MHExpoJakarta2024 #LebihDekatLebihTerjangkau

Malaysia Healthcare Travel Council (MHTC), founded in 2009 and operating under the purview of Ministry of Health (MOH) Malaysia, is tasked with developing and nurturing the “Malaysia Healthcare” brand. MHTC enhances, coordinates, and promotes Malaysia’s healthcare travel industry by fostering industry collaborations and establishing valuable public-private partnerships both domestically and internationally. Working with over 92 private hospitals across Malaysia, MHTC aims to elevate the healthcare travel industry through an active ecosystem, a robust “Malaysia Healthcare” brand, and strategic market initiatives. The “Malaysia Healthcare” brand aspires to position Malaysia as the premier global healthcare destination. As a significant export service, Malaysia’s healthcare travel industry plays a vital role in the nation’s economy.

Source

QINGDAO, China, July 26, 2024 /PRNewswire/ — As the world’s biggest sporting occasion gets underway, Hisense, a global leader in consumer electronics and appliances is igniting sporting passions direct from Paris with its ‘Big Game, Big Screen’ campaign.

Highlight of Hisense’s ongoing global promotional campaign is the awe-inspiring 100-inch U7 ULED TV, transforming any living room into the ultimate viewing arena and bringing all the excitement of elite athletic endeavor into the home on the big screen, thanks to ULED TV 100-inch display technology.

Hisense ranked global No.1 for 100-inch TVs in both 2023 and Q1 2024, and is on track to winning-over dedicated sports fans in embracing the 100-inch TV era with the industry’s largest size of LED TVs.

Settle in to enjoy all the world’s best athletic and sports action this August with 100-inch immersive viewing experiences across a wide-range of Hisense TV product lines offering the very latest in picture and audio technologies. 

A podium-winning stand out TV in the Hisense product series is the U7 Mini-LED ULED which features a native 120Hz refresh rate and AI Sports Mode that removes “noises” using a dynamic algorithm tailored to moving objects, creating vibrant, crystal-clear sports action viewing.

Hisense state-of-the-art LED backlight control and color management technologies ensure the brightest sharpest pictures, while the Hisense Hi-View Engine elevates and enhances overall picture quality with authentic color, brilliant contrast, clear motion, and distinct details.

Designed to ensure an unparalleled immersive experience the U7 ULED TV will transform your sports viewing to gold-medal standards. Thanks to Hisense and 100-inch viewing, major sporting experiences will never be quite the same.

About Hisense

Hisense is a leading global home appliance and consumer electronics brand and official partner of the UEFA EURO 2024™. According to Omdia, Hisense ranked No. 2 globally for TV shipments and No. 1 in 100″ TVs in both 2023 and Q1 2024. The company has expanded quickly to operate in more than 160 countries and specializes in multi-media goods, home appliances, and intelligent IT information.

Source

BEIJING, July 26, 2024 /PRNewswire/ — Boasting rich wetland resources, Harbin City in northeast China’s Heilongjiang Province has become a popular tourism destination in summer days this year.

Since the start of July, the search volume for “wetlands” in Harbin on Chinese e-commerce platform Meituan has increased 23 percent year on year, with the number of related travel tips surging 151 percent year on year, according to data from Meituan.

Recently, the number of tourist visits to the Hulan River estuary wetland park has significantly increased, reaching about 5,000 on weekends, according to Zhang Huan, the park’s operation manager.

The park gives priority to wetland ecosystem conservation. Meanwhile, it provides diversified services for visitors to do exercises and enjoy recreational activities.

As one of the Chinese cities certified as “International Wetland Cities”, Harbin has been stepping up wetland conservation and restoration efforts.

It has implemented the medium- and long-term wetland protection plan (2019-2035), and rolled out wetland protection measures, a work plan for wetland ecological conservation and restoration, as well as an implementation plan for the enforcement of the national wetland protection law, securing law-based protection endeavors aiming to enhance the quality of wetlands, according to Xing Guangyou, director of wetlands and natural reserves management division of Harbin municipal forestry and grassland administration.

Wetland parks have established relevant management mechanisms. For example, Alejin Island national wetland park has introduced wetland protection management system, wildlife protection and rescue system, water quality monitoring and management system and so on. The national level wetland park covers an area of 419 hectares, of which 71.1 percent are wetlands.

Through years of efforts, Harbin has restored more than 3,000 hectares of wetlands, and reverted cultivated land into 685 hectares of wetlands.

Harbin’s achievements in wetland protection have earned good returns. Approximately one million tourist visits are made to Harbin each year, creating a total income hitting tens of billions of yuan for the city.

See the original link: https://en.imsilkroad.com/p/341314.html  

Source

• HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products.
• HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERA^TM) technology, targeting ophthalmic and otic diseases.
• Progress in clinical development programs continued including the completion of Phase 1 study for HL192 (ATH-399A) in Parkinson’s Disease, with results expected in the second half of 2024 and initiation of VELOS-4 Phase 3 study on tanfanercept for Dry Eye Disease.

ROCKVILLE, Md. and SEOUL, South Korea, July 26, 2024 /PRNewswire/ — HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the second quarter of 2024 and provided business updates.

HanAll ended the second quarter with total revenue of 31.6 billion KRW and an operating loss of 3.1 billion KRW. Sales revenue reached 28.1 billion KRW, reflecting a 5.4% increase from the same period in 2023, bolstered by robust sales of key products. The overall profitability for the second quarter turned to a loss due to the absence of milestone revenues from the licensed partner.

Within the past quarter, HanAll strengthened its relationship with Turn Biotechnologies, a company founded on licensed technologies from Stanford, culminating in an exclusive licensing agreement to explore the potential of transient epigenetic reprogramming with the use of Yamanaka factors for ophthalmic and otic diseases.

HanAll also completed a Phase 1 first in human study of HL192 (ATH-399A) targeting Parkinson’s Disease, with results anticipated in the second half of 2024.

HanAll’s research and development efforts have achieved significant progress with the initiation of the Phase 3 VELOS-4 study investigating tanfanercept for dry eye disease (DED), with the topline results expected in 2026.

Progress in anti-FcRn assets continued, with the potential advancement of HL161ANS (IMVT-1402)’s development program. Top-line results are anticipated from the ongoing batoclimab Phase 2b study in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Phase 3 study in generalized Myasthenia Gravis (gMG) in the first quarter of 2025. Additionally, the resubmission of the Biologics License Application (BLA) in China for gMG marked a significant milestone, bringing batoclimab one step closer to commercialization.

A total of 10 additional studies are being planned for HL161ANS (IMVT-1402). The initiation of studies for the first 4 to 5 potentially registrational studies is slated to begin by the first quarter of 2025. The remaining indications are slated to be initiated by the first quarter of 2026.

“HanAll made a meaningful progress in our R&D in the second quarter, including the completion of the HL192 Phase 1 study in PD, the initiation of the VELOS-4 Phase 3 study for dry eye, and the establishment of a licensing agreement with Turn.bio to develop medicines for age-related diseases. We will sustain our investment in R&D through enhancing efficiency of our operations,” said Sean Jeong, M.D., MBA, CEO of HanAll Biopharma.

Second Quarter 2024 BUSINESS UPDATE

Pipeline Development Highlights

A comprehensive update of HanAll’s public pipeline development below includes an overview of research along with lists of compounds, targeted indications, and developmental phases.

AUTOIMMUNE DISEASES PROGRAMS

Batoclimab (HL161BKN)

A novel, fully human, subcutaneously administered antibody targeting FcRn with the potential to address multiple IgG-mediated autoimmune diseases, batoclimab is designed to selectively bind to FcRn, which plays a role in recycling IgG, thereby reducing levels of harmful IgG antibodies

• Immunovant, a member of the Roivant group of companies as well as HanAll’s licensed partner in the United States and Europe, is making progress across four autoimmune indications. Results from the batoclimab study in Graves’ disease are expected in fall of 2024 from Immunovant. Phase 3 studies in gMG and TED are advancing.
• Topline data from the Phase 3 study in generalized Myasthenia Gravis (gMG) is also anticipated in the first quarter of 2025.
• Progress continues in the Phase 3 study for Thyroid Eye Disease (TED), with the top-line results also projected in the first half of 2025.
• Regarding the ongoing Phase 2b Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) study, Immunovant has decided to extend the duration of the study in order to optimize the study design for IMVT-1402 in CIDP. Following this decision, initial results from period 1 of the Phase 2b study in CIDP are expected in the first quarter of 2025.
• Harbour BioMed, another licensed partner which transferred exclusive rights to develop, manufacture, and commercialize batoclimab in the Greater China region to CSPC NBP Pharmaceuticals Co., Ltd. (NBP Pharma), has resubmitted the Biologics License Application (BLA) for batoclimab to the National Medical Products Administration (NMPA) in June 2024. The BLA incorporated supplementary long-term safety data from the Phase 3 study in gMG, concluded in June 2023.

HL161ANS (IMVT-1402)

Another novel, fully human, subcutaneous antibody molecule that inhibits FcRn-mediated recycling of IgG is designed to deliver maximum lgG reductions, while minimizing interference with albumin recycling

• Immunovant plans to initiate 4 to 5 potentially registrational studies for IMVT-1402 (HL161ANS) before the end of first quarter of 2025, following a recent Type B meeting with the FDA (Food and Drug Administration). The company plans to initiate studies on IMVT-1402 in a total of 10 indications before the end of the first quarter of 2026.
• Immunovant is exploring initiating a registrational development in gMG with IMVT-1402.
• Immunovant will work to optimize the HL161ANS/IMVT-1402 CIDP trial design, drawing insights from the ongoing CIDP Phase 2b trial for batoclimab. This process involves extending the duration of Phase 2b study in batoclimab in CIDP and incorporating learnings from the previous studies.
• Immunovant also plans to provide an overview of the development program for HL161ANS/IMVT-1402 in Grave’s disease (GD) in the second half of 2024.

OPHTHALMIC DISEASE PROGRAM

Tanfanercept (HL036)

A novel topical protein therapy for ophthalmic diseases, including dry eye disease (DED), which inhibits TNF, a key mediator of ocular inflammation

• HanAll Biopharma and Daewoong Pharmaceutical initiated the Phase 3 VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye. The topline results for the VELOS-4 study is expected in 2026.
• The Phase 3 VELOS-4 trial builds upon key insights gained from the completed Phase 3 VELOS-3 study. In VELOS-3, tanfanercept demonstrated a statistically significant improvement in the secondary efficacy endpoint of tear volume, as measured by unanesthetized Schirmer testing, in patients treated with tanfanercept compared to those in the vehicle group at week 8 (p=0.002). In addition, a post hoc analysis revealed that a notable proportion of participants in the tanfanercept group (14%) showed significant improvement (p=0.011) in the Schirmer test, with an increase of at least 10mm from baseline at week 8, compared to only 4% in the vehicle group.
• The 2020 FDA Draft Guidance on Dry Eye Drug Development considers the proportion of participants achieving a minimum 10mm increase in the Schirmer test response rate as an acceptable primary efficacy endpoint for approval.

NEUROLOGY PROGRAM

HL192 (ATH-399A)

A pipeline candidate from NurrOn Pharmaceuticals (originating from Harvard Medical School’s Molecular Neurobiology Laboratory) which targets Nurr1, both a master regulator in dopaminergic neuron development and maintenance, as well as an important component in anti-inflammatory functions. HL192 (ATH-399A) is being developed to treat neurodegenerative diseases, including Parkinson’s disease (PD).

• The Phase 1 study of HL192, being jointly developed by HanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Pharmaceuticals, has completed dosing with the results expected in the second half of 2024.

ONCOLOGY PROGRAMS

HL187 is a monoclonal antibody that targets TIGIT (T cell immunoreceptors with Ig and ITIM domains {Immunoreceptor tyrosine-based inhibitory motif domains}). HL186 is a monoclonal antibody that targets TIM-3 (T cell Ig and mucin domain-3). These antibodies are being developed in collaboration with Daewoong Pharmaceutical as potential oncology treatments.

• HanAll is continuing with the pre-clinical development of the HL187 (anti-TIGIT) asset and plans to evaluate the further development of HL186 (anti-TIM-3) based on the strategic portfolio review.

About HanAll Biopharma

HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with presence in Korea, the USA, Japan, and Indonesia with the mission of making meaningful contributions to patients’ lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in the therapeutic areas of endocrine, circulatory, and urologic diseases for over 50 years.

HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline assets, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’ disease (GD). HL161ANS (IMVT-1402), an anti-FcRn antibody targeting multiple indications, is being evaluated in a Phase clinical study (healthy volunteers).

Another lead asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and is also being evaluated in China for the treatment of dry eye disease.

HL192 (ATH-399A), a Nurr1 activator targeting Parkinson’s Disease, has completed a Phase 1 study in healthy volunteers.

For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR (pr@hanall.com, ir@hanall.com).

Disclaimer Statement 

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” or “should,” and include statements HANALL (the company, we) makes concerning its 2024 business and financial outlook and related plans; the therapeutic potential of its product candidates; the intended results of its strategy and the company, and its collaboration partners’, advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company’s actual results may differ materially from those predicted by the forward-looking statements. These may include various significant factors, such as our expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities, and regulatory approval requirements. In addition, performance may be affected by our reliance on collaborations with third parties, estimating the commercial potential of our product candidates, our ability to obtain and maintain protection of intellectual property of technologies and drugs, our limited operating history, and our ability to obtain additional funding for operations and to complete the development and commercialization of product candidates. A further list and description of these risks, uncertainties, and other risks can be found in Korea Stock Exchange (KRX) filings and reports, including in our most recent annual report as well as subsequent filings and reports filed by the company with the KRX. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. We undertake no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by Korean law and regulations. 

Source